[1] 李子月, 杨士田, 吴玲玲, 等. 乙型肝炎病毒相关慢加急性肝衰竭患者预后危险因素分析及预后模型建立. 中华传染病杂志, 2019, 37(12): 737-741. [2] Tergast TL, Schultalbers M, Wedemeyer H, et al. IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis? J Hepatol, 2021, 75(1): 229-231. [3] Sun J, Guo H, Yu X, et al. Evaluation of prognostic value of neutrophil-to-lymphocyte ratio in patients with acute-on-chronic liver failure or severe liver injury from chronic HBV infection. Eur J Gastroenterol Hepatol, 2021, 33(1S): e670-e680. [4] de Souza CP, Alves B, Waisberg J, et al. Detection of COX-2 in liquid biopsy in patients with breast cancer. J Clin Pathol, 2020, 73(12): 826-829. [5] 陈海鸥, 刘适. 慢加急性乙型肝炎肝衰竭患者血清IL-10和GP73水平检测及其临床意义. 实用肝脏病杂志, 2019, 22(1): 73-76. [6] 中华医学会感染病学分会肝衰竭与人工肝学组, 肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版). 实用肝脏病杂志, 2013, 16(3): 210-216. [7] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版). 实用肝脏病杂志, 2016, 19(3): 389-400. [8] 白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析. 实用肝脏病杂志, 2019, 22(4): 490-493. [9] Balcar L, Semmler G, Pomej K, et al. Patterns of acute decompensation in hospitalizedpatients with cirrhosis and course of acute-on-chronic liver failure. United European Gastroenterol J, 2021, 9(4): 427-437. [10] 黄少军, 程瑾, 汪晶晶, 等. 乙型肝炎病毒相关慢加急性(亚急性)肝功能衰竭患者外周血单个核细胞中干扰素诱导蛋白-10的水平及其对预后的判断价值. 中华传染病杂志, 2018, 36(6): 340-344. [11] Chen J, Xu Q, Zhang Y, et al. RNA profiling analysis of the serum exosomes derived from patients with chronic hepatitis and acute-on-chronic liver failure caused by HBV. Sci Rep, 2020, 10(1): 1528-1528. [12] Yang F, Liu Y, Zeng B, et al. Noninvasive assessment of liver fibrosis for predicting acute-on-chronic liver failure in patients with chronic hepatitis B. Hepatol Int, 2021, 15(3): 593-601. [13] Chen L, Ji X, Wang M, et al. Involvement of TLR4signaling regulated-COX2/PGE2 axis in liver fibrosis induced by schistosoma Japonicum infection. Parasit Vect, 2021, 14(1): 279-279. [14] Mitra B, Wang J, Kim ES, et al. Hepatitis Bvirus precore protein p22 inhibits interferon-alpha signaling by blocking STAT nuclear translocation. J Virol, 2019, 93(13): e00196-219. [15] Takahashi N, Hayashi K, Nakagawa Y, et al. Development of an anti-hepatitis B virus (HBV) agent through the structure-activity relationship of the interferon-like small compound CDM-3008. Bioorg Med Chem, 2019, 27(3): 470-478. [16] Kosumi K, Hamada T, Zhang S, et al. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. Eur J Cancer, 2019, 111(4): 82-93. [17] Hatatian N, Bosstani R, Mohammadi A, et al. Evaluation of interleukin-32 and cyclooxygenase-2 expression in HAM/TSP patients and HTLV-1 asymptomatic carriers. Iran J Basic Med Sci, 2021, 24(7): 992-996. [18] Alaaeddine RA, Elzahhar PA, AlZaim I, et al. Theemerging role of COX-2, 15-LOX, and PPARγ in metabolic diseases and cancer: An introduction to novel multi-target directed ligands (MTDLs). Curr Med Chem, 2021, 28(11): 2260-2300. [19] Huang Z, Ma X, Jia X, et al. Prevention ofsevere acute pancreatitis with cyclooxygenase-2 inhibitors: A randomized controlled clinical trial. Am J Gastroenterol, 2020, 115(3): 473-480. [20] Xu D, Cai J, Wan ZK, et al. Pathophysiological role of prostaglandin E synthases in liver diseases. Prostaglandins Other Lipid Mediat, 2021, 154(9): 106552. |